The Plot...

Excella Pharmaceutical's ground-breaking diet drug is in the midst of the FDA's final phase of testing when volunteer subjects begin mysteriously dropping out of the study. The drug's inventor, Dr. Jack Finnegan, starts investigating the new developments, only to find himself dangerously mired in a twisted maze of greed, deceit, and organized crime. With patients and profits suddenly at grave risk, his only hope lies in a cutting-edge clinical psychiatrist, Alison Sonders, MD, who helps him unravel the complex relationship between overeating, mood, and dieting in this fast-paced medical thriller.

More Information:

This is no ordinary story about a stimulant diet pill with the usual side effects. Ascendiac® was different from the day it was discovered. Dr. Jack Finnegan knew the science was sound and that this drug represented a huge leap forward in the treatment of overeating and obesity. The drug successfully suppressed the user's appetite by utilizing the same neurotransmitters the body relies upon every day in the regulation of hunger. Excella had proven it could decrease appetite, but the US Food and Drug Administration requires proof that it's safe for the people who are expected to use it. The final trial they require before approval is known as "The Phase 3 Study." That's where Ascendiac® is now, but the real work for Jack and his team has yet to begin....

Dr. Wambold researched the scientific basis of hunger extensively before writing Ascendiac®. A prominent chemist from a well-known pharmaceutical company admitted that there was a significant effort underway to develop just such a drug. When they compared notes, both were surprised to find that they had found similar evidence that just such an approach to weight management might well succeed. Read the novel now, before it's front page news.